Thursday, July 10, 2014
its founding in 2010, Ember Therapeutics Inc. has been exploiting
the biology of brown and beige fat to treat metabolic diseases, including
obesity and type 2 diabetes. Now, the biotech has an option to license the
hormone meteorin glial cell differentiation regulator-like,
one of the first molecules found to activate a newly identified immune system-regulated
pathway responsible for driving the formation of beige fat.1,2
The new data could spur efforts to investigate other
immune system components as therapeutics that promote the development of beige
K.-J. SciBX 7(26);
Published online July 10, 2014
1. Rao, R.R. et al.
Cell; published online June 5, 2014;
Contact: Bruce Spiegelman, Dana-Farber Cancer Institute, Boston, Mass.
2. Qiu, Y. et al. Cell;
published online June 5, 2014;
Contact: Ajay Chawla, University of California, San Francisco, Calif.
3. Harms, M. & Seale,
P. Nat. Med. 19, 1252-1263 (2013)
AND INSTITUTIONS MENTIONED
Brigham and Women's Hospital, Boston, Mass.
Dana-Farber Cancer Institute, Boston, Mass.
Ember Therapeutics Inc., Boston, Mass.
Harvard Medical School, Boston, Mass.
Perelman School of Medicine at the University of
University of California, San Francisco, Calif.
University of Gothenburg, Gothenburg, Sweden